Oppenheimer resumed coverage on Insulet with a new price target
$PODD
Medical/Dental Instruments
Health Care
Oppenheimer resumed coverage of Insulet with a rating of Outperform and set a new price target of $365.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/23/2026 | $190.00 | Buy | Deutsche Bank |
| 5/20/2026 | Outperform | William Blair | |
| 4/24/2026 | $220.00 | Buy → Neutral | Rothschild & Co Redburn |
| 4/7/2026 | $230.00 | Buy → Neutral | Citigroup |
| 1/27/2026 | $294.00 | Hold | TD Cowen |
| 1/12/2026 | $274.00 | Overweight → Equal Weight | Barclays |
| 12/16/2025 | $370.00 | Outperform | Evercore ISI |
| 11/19/2025 | $400.00 | Neutral → Buy | UBS |
8-K - INSULET CORP (0001145197) (Filer)
SD - INSULET CORP (0001145197) (Filer)
8-K - INSULET CORP (0001145197) (Filer)
The partnership introduces The Mind in Range Collection, a set of tailored mindfulness resources available at no cost to the diabetes community, including a meditation series, a breathing exercise, and a new Calm Sleep Story narrated by Omnipod® user and fashion model Lila Moss, designed to help listeners unwind and feel supported With 359 million people worldwide living with an anxiety disorder1, and people with diabetes being 20% more likely to develop anxiety2, this initiative reinforces Insulet’s commitment to whole-person care and positions mental health as essential to diabetes management The integrated content collaboration is the first-of-its-kind between Calm and a MedTe
Omnipod 5 Automated Insulin Delivery System now available in 20 countries worldwide New web-based data platform Omnipod Discover simplifies diabetes insights for users, caregivers, and healthcare professionals Omnipod 5 launch in Spain is compatible with Abbott and Dexcom continuous glucose monitoring systems Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the commercial launch of its Omnipod 5 Automated Insulin Delivery System and its proprietary data management system Omnipod Discover™ in Spain, the Company’s newest European market. Spain is the 26th country whe
Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it will report financial results for the second quarter of 2026 on Wednesday, August 5, 2026, before the opening of the financial markets. In connection with the release, management will host a conference call that day at 8:00 a.m. (Eastern Time). The link to the live call will be available on the Investor Relations section of the Company's website at investors.insulet.com, "Events and Presentations," and will be archived for future replay. You may also access the live call by dialing (888) 770-7129 for domestic callers, or
4 - INSULET CORP (0001145197) (Issuer)
4 - INSULET CORP (0001145197) (Issuer)
4 - INSULET CORP (0001145197) (Issuer)
Deutsche Bank initiated coverage of Insulet with a rating of Buy and set a new price target of $190.00
William Blair resumed coverage of Insulet with a rating of Outperform
Rothschild & Co Redburn downgraded Insulet from Buy to Neutral and set a new price target of $220.00
4/A - INSULET CORP (0001145197) (Issuer)
4 - INSULET CORP (0001145197) (Issuer)
3 - INSULET CORP (0001145197) (Issuer)
SC 13G/A - INSULET CORP (0001145197) (Subject)
SC 13G/A - INSULET CORP (0001145197) (Subject)
SC 13G/A - INSULET CORP (0001145197) (Subject)
Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it will report financial results for the second quarter of 2026 on Wednesday, August 5, 2026, before the opening of the financial markets. In connection with the release, management will host a conference call that day at 8:00 a.m. (Eastern Time). The link to the live call will be available on the Investor Relations section of the Company's website at investors.insulet.com, "Events and Presentations," and will be archived for future replay. You may also access the live call by dialing (888) 770-7129 for domestic callers, or
Raises Full Year Total Company Revenue Guidance Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its financial results for the three months ended March 31, 2026. First Quarter Financial Highlights: Revenue of $761.7 million, up 33.9%, or 30.1% in constant currency1, and exceeded the high end of the Company's guidance range of 25% - 27% at constant currency rates Total Omnipod revenue of $758.4 million, rose 36.9%, or 33.0% in constant currency U.S. Omnipod revenue of $515.6 million, increased 28.3% International Omnipod revenue of $242.9 million, increased 59.4
Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it will report financial results for the first quarter of 2026 on Wednesday, May 6, 2026, before the opening of the financial markets. In connection with the release, management will host a conference call that day at 8:00 a.m. (Eastern Time). The link to the live call will be available on the Investor Relations section of the Company's website at investors.insulet.com, "Events and Presentations," and will be archived for future replay. You may also access the live call by dialing (888) 770-7129 for domestic callers, or (929
Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the appointment of Jonathan ("Jay") Mazelsky to the Company’s Board of Directors, effective July 1, 2026. Mr. Mazelsky joins the Board as an independent director. "We are pleased to welcome Jay to Insulet’s Board of Directors," said President and CEO Ashley McEvoy. "Jay has a strong track record of translating science into solutions to drive growth and create significant and enduring shareholder value. His background and expertise will be integral as Insulet continues to expand access and further strengthen Omnipod’s leaders
Insulet Corporation (NASDAQ:PODD) ("Insulet" or the "Company"), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the appointment of Mike Panos as Executive Vice President, Chief Commercial Officer, effective immediately. In this role, Mr. Panos will lead Insulet's global commercial organization, reporting to President and Chief Executive Officer Ashley McEvoy. He will also be a member of the Executive Leadership Team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330524787/en/ "We have a significant growth opportunity in front of us, driven by strong clinical outcomes
Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the appointment of Robert ("Robbie") L. Huffines, a former Global Chair of Investment Banking at JP Morgan Chase & Co., to the Company's board of directors, effective October 31, 2025. Mr. Huffines joins the board as an independent director and will serve on the board's Audit Committee. "We are honored to welcome Robbie to Insulet's Board of Directors," said Timothy Scannell, Chairman of the Board. "Robbie brings more than three decades of distinguished experience advising healthcare companies at one of the world's leading f